{"title":"Detection of serum lactate dehydrogenase A and its metabolites on placental function in patients with intrahepatic cholestasis of pregnancy.","authors":"Huan Huang, Jianyi Gao, Ruirui Dong, Rong Wang, Ling Li, Gaoying Wang, Yingxian Shi, Kailin Luo, Jing Chen, Wenqing Yuan, Xiaoxue Tian, Haijian Zhao, Ting Zhang","doi":"10.1016/j.intimp.2024.113739","DOIUrl":null,"url":null,"abstract":"<p><p>A specific liver disease during pregnancy is intrahepatic cholestasis of pregnancy (ICP). The current clinical diagnosis mainly depends on the level of serum total bile acid (TBA), which lacks sensitivity and specificity. Lactate dehydrogenase A (LDHA) is a new biomarker highly expressed in the serum of ICP patients, which was screened by data-independent acquisition (DIA) proteomic technology in our previous studies. There is currently a lack of a rapid, quantitative, and sensitive detection method to measure LDHA levels in serum. This study aimed to establish a time-resolved fluorescent nanomicrospheres immunochromatographic test strip to detect LDHA in serum and evaluate its value in clinical diagnosis and treatment of ICP. Subsequently, the mechanism of LDHA in mediating the inflammatory of ICP was explored in vitro. In vitro, taurocholic acid (TCA) at a concentration of 100 μM was used to simulate an ICP environment. The AKT/mTOR/HIF-1α signaling pathway was activated in TCA-treated HTR-8/SVeno cells, leading to an increase in LDHA levels. The lactic acid produced by LDHA-mediated glycolytic metabolism may be related to the regulation of inflammation in placental trophoblast cells. According to these findings, LDHA could be a new target that provide promising ideas for the diagnosis, prediction and treatment of ICP.</p>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"145 ","pages":"113739"},"PeriodicalIF":4.8000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.intimp.2024.113739","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A specific liver disease during pregnancy is intrahepatic cholestasis of pregnancy (ICP). The current clinical diagnosis mainly depends on the level of serum total bile acid (TBA), which lacks sensitivity and specificity. Lactate dehydrogenase A (LDHA) is a new biomarker highly expressed in the serum of ICP patients, which was screened by data-independent acquisition (DIA) proteomic technology in our previous studies. There is currently a lack of a rapid, quantitative, and sensitive detection method to measure LDHA levels in serum. This study aimed to establish a time-resolved fluorescent nanomicrospheres immunochromatographic test strip to detect LDHA in serum and evaluate its value in clinical diagnosis and treatment of ICP. Subsequently, the mechanism of LDHA in mediating the inflammatory of ICP was explored in vitro. In vitro, taurocholic acid (TCA) at a concentration of 100 μM was used to simulate an ICP environment. The AKT/mTOR/HIF-1α signaling pathway was activated in TCA-treated HTR-8/SVeno cells, leading to an increase in LDHA levels. The lactic acid produced by LDHA-mediated glycolytic metabolism may be related to the regulation of inflammation in placental trophoblast cells. According to these findings, LDHA could be a new target that provide promising ideas for the diagnosis, prediction and treatment of ICP.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.